NCEPOD are exploring the process of the transition of young people with complex chronic conditions from child to adult health services.
The aim of the study is to explore the barriers and facilitators in the process of the transition of young people with complex chronic conditions from child to adult health services.
Information is being collected from primary, community, physical and mental healthcare settings.
Due to the pressure on hospital teams during the COVID pandemic, we postponed the 2021 competition but are now launching a revamped award for 2022 which has been amended to take into account the current COVID situation. We are inviting colleagues to submit entries which will be for:
We have now launched the annual census of Consultants in Diabetes and Endocrinology. This is being done on behalf of ABCD, SfE, Diabetes UK and The Royal College of Physicians London who are also project managing this census.
There has never been a more important time to gather information about how were all working and the impact our jobs have on our lives.
NCEPOD are undertaking a study to look at the process of transition from child to adult health services. As part of this study, they are collecting the views of young people and parent carers on the transition process via an online survey.
The link to share with any relevant patient/ parent groups is https://ncepod.qualtrics.com/jfe/form/SV_5t0grqVhJMWrzsW
The survey will be open until May 2022
Today, 17th December 2021, ABCD publishes the results of the Integrated survey about diabetes services.
https://bjd-abcd.com/index.php/bjd/article/view/781
Please find the link to the raw data of this survey below.
As of 25th October 2021, dapagliflozin 5mg is no longer authorised for the treatment of people with type 1 diabetes mellitus (T1DM) and should no longer be used in this population . This is based on AstraZeneca’s decision to remove the Type 1 diabetes indication for dapagliflozin 5mg.
ABCD are disappointed that the use of dapaglifozin has been withdrawn for people with type 1 diabetes.
This is not due to any safety concern for dapagliflozin in any indication, including people with type 1 diabetes.
Raunak Chugani Chandiramani, Laura Storey, Mina Mansor, Neil Hill
Imperial College London
Melvin Lee Yoong Zher, Andrew Pettit
Department of Diabetes and Endocrinology, Division of Internal Medicine, Airedale General Hospital
Yin WL; Wong E; Moses J; Minton D; Hussain R; Obuobie K
oyal Gwent Hospital, Newport, Ysbyty Ystrad Fawr, General Practice; Aneurin Bevan University Health Board
